Naz News, Gappers and FLE's

[iconoclassic]

COR, 3.62, gapped again, up .23 now (EDIT) news yesterday...Cortex ADHD drug shows promise in phase II trial




--------------------------------------------------------------------------------
Tue Mar 07 13:00:04 2006 EST
Mar 07, 2006 (Datamonitor via COMTEX) --
Cortex Pharmaceuticals' lead ampakine drug CX717 has shown positive results in
the treatment of adults with ADHD in a phase IIa trial.
Cortex undertook this phase IIa clinical trial to assess both the dose of
drug required and the effectiveness of CX717 in an adult ADHD population. The primary
outcome measure was the ADHD Rating Scale (ADHD-RS) which evaluates both the inattentiveness
and hyperactivity symptoms.
The overall ADHD-RS score showed a positive trend in the 800mg twice daily
dose group, with a statistically significant effect on the hyperactivity subscale
compared to placebo. The 200mg twice daily dose did not show a significant effect
however.
CX717 was well tolerated, and there were no serious adverse events or other
significant safety concerns with either dose. Furthermore, no increases in blood
pressure or heart rate were observed with either dose of CX717.
"The results from this phase IIa study in adults with ADHD show that CX717
provided a clinically relevant response on the ADHD Rating Scale though the results
will need to be verified in a larger study," said Dr Lenard Adler, the lead investigator
of the study, director for the Adult ADHD Program, and associate professor of psychiatry
and neurology at New York University School of Medicine. "I am encouraged by the
performance of CX717 which could lead to the development of a new pharmacotherapy
for the treatment of ADHD."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon


Copyright (C) 2006 Datamonitor. All rights reserved